Casdatifan
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Casdatifan
- Structure (SMILES)
- c1cc(c2c(c1S(C)(=O)=O)[C@@H]([C@@H](C2)F)O)[C@@]3(c4c(cc(F)cc4C#N)[C@H]([C@H](C3)F)F)[H]
- ab 521
- AB-521
- ab521
- AB521
- casdatifan
- Casdatifan
- casdatifan [INN]
- CASDATIFAN [USAN]
- Casdatifan [WHO-DD]
- casdatifan inn
- casdatifan usan
- casdatifan who dd
- CAS registry numbers
- 2709069-30-5
- ChEMBL ID
- CHEMBL6068220
- InChIKey
- KHBHHNNBNHHGPE-QCCZFBHPSA-N
- PubChem compound IDs
- 156859185
- FDA ingredient codes (UNII)
- DP73UWL6LE
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- casdatifan
- Type
- Synthetic organic
- Drug name stem
- -ifan
Mechanisms of action
- Action
- Binding
- Action type
- Binding
- Target
- endothelial PAS domain protein 1
- Gene symbol
- EPAS1
- Protein identifier
- Q99814
- Median affinity
- 7.54
- Affinity units
- pIC50
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005005
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005070
- Calculated partition coefficient (XLogP)
- 3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 30
- Monoisotopic mass
- 439.08652723
- Natural product
- No
Related records
Trials (12)
- A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
- Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function
- Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
- Pilot Study of Casdatifan-Treated Refractory Renal Cell Carcinoma
- Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
- Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
- Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers
In development for (1)
- Neoplasm Phase 2